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Obesity and obesity-associated disorders have become world-wide epidemics,
substantially increasing the risk of debilitating morbidity and mortality. A characteristic
feature of these disorders, which include the metabolic syndrome (MetS) and type 2
diabetes, is chronic low-grade inflammation stemming from metabolic and immune
dysregulation. Inflammation in the CNS (neuroinflammation) and cognitive impairment
have also been associated with obesity-driven disorders. The nervous system has a
documented role in the regulation of metabolic homeostasis and immune function, and
recent studies have indicated the important role of vagus nerve and brain cholinergic
signaling in this context. In this review, we outline relevant aspects of this regulation with
a specific focus on obesity-associated conditions. We outline accumulating preclinical
evidence for the therapeutic efficacy of cholinergic stimulation in alleviating obesity-
associated inflammation, neuroinflammation, and metabolic derangements. Recently
demonstrated beneficial effects of galantamine, a centrally acting cholinergic drug and
cognitive enhancer, in patients with MetS are also summarized. These studies provide a
rationale for further therapeutic developments using pharmacological and bioelectronic
cholinergic modulation for clinical benefit in obesity-associated disorders.
Keywords: cholinergic, brain, vagus nerve, obesity, metabolic syndrome, inflammation, neuroinflammation,
cognition
INTRODUCTION
Obesity and obesity-related disorders have become prevalent conditions in our modern society,
impacting over 1 billion people worldwide (Zimmet et al., 2001; Grundy, 2008; Aguilar et al., 2015;
Kim et al., 2019). Obesity and the closely related metabolic syndrome (MetS) generate a substantial
risk of developing type 2 diabetes, cardiovascular disease, and other debilitating and life-threatening
diseases (Eckel et al., 2005; Grundy, 2008; van Dieren et al., 2010). Therefore, treating these
conditions is of primary importance. Diet and exercise are key approaches, but in many cases
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these lifestyle modifications are either not sustainable or
difficult to implement. Clearly, there is a considerable
need for better understanding of the complex pathology
underlying obesity-driven disorders and for strategizing
novel therapeutic approaches. Obesity-related chronic low-
grade inflammation provides an important link to metabolic
derangements including insulin resistance in these disorders
(Shoelson et al., 2007). In addition to peripheral inflammation,
inflammation in the CNS (neuroinflammation), affecting the
hypothalamus and other brain regions, has also been described
and associated with cognitive impairment in the context
of obesity (Guillemot-Legris and Muccioli, 2017). Multiple
links between peripheral and brain alterations, involving
inflammatory, metabolic, and neural components, have been
identified in obesity-associated conditions (Schwartz and
Porte, 2005; Pavlov and Tracey, 2012). Of note, the role of the
nervous system in this relationship has been a specific focus of
ongoing research. The nervous system and the brain regulate
feeding behavior, energy intake and expenditure, and metabolic
homeostasis (Pavlov and Tracey, 2012; Kaelberer et al., 2018).
The vagus nerve (the tenth cranial nerve), which contains fibers
carrying ascending sensory signals to the brain and descending
motor signals to the visceral organs, is importantly involved in
these regulatory processes (Pavlov et al., 2018).
The nervous system also communicates with the immune
system (Dantzer, 2018; Pavlov et al., 2018), and research during
the last 20 years has revealed the important role of the vagus
nerve in this communication. A body of preclinical evidence
has demonstrated that the vagus nerve regulates inflammatory
responses within a physiological mechanism termed the
inflammatory reflex (Tracey, 2002; Pavlov et al., 2003).
Accordingly, electrical vagus nerve stimulation (VNS) has been
shown to control the release of pro-inflammatory cytokines and
aberrant inflammation in many conditions (Chavan et al., 2017;
Pavlov and Tracey, 2017). The mechanisms of the inflammatory
reflex, which will be discussed in more detail later, involve alpha7
nicotinic acetylcholine receptor (α7nAChR)-mediated signaling
in its efferent arm. Cholinergic compounds, including α7nAChR
agonists and centrally acting acetylcholinesterase inhibitors
(AChE), have also been shown to alleviate inflammation and
metabolic derangements in obesity and MetS (Pavlov and
Tracey, 2012). One of these drugs, the centrally acting AChE
inhibitor galantamine is in clinical use for counteracting
cognitive impairment in Alzheimer’s disease (Hampel et al.,
2018). A recent clinical trial revealed the anti-inflammatory and
beneficial metabolic effects of galantamine in patients with MetS
(Consolim-Colombo et al., 2017). Recent clinical studies also
demonstrated the utility of bioelectronic VNS in rheumatoid
arthritis and inflammatory bowel disease (IBD) – conditions
characterized by immune and metabolic dysregulation (Bonaz
et al., 2016; Koopman et al., 2016). Future applications of VNS in
the arena of MetS and other obesity-driven disorders are feasible
and of significant interest.
In this review, we briefly summarize the role of brain
and the vagus nerve cholinergic signaling in the regulation
of metabolic homeostasis and the role of the vagus nerve-
based inflammatory reflex in controlling inflammation. We
further point to important aspects of the relationship between
inflammation, metabolic deterioration, neuroinflammation, and
cognitive impairment in obesity-driven disorders. In this context,
we elaborate on accumulating pre-clinical and clinical evidence
for therapeutic benefit of stimulating brain and vagus nerve
cholinergic signaling. We also consider the potential benefit
of enhancing cholinergic signaling by centrally acting AChE
inhibitors and VNS for counteracting cognitive deterioration in
obesity-driven conditions.
THE BRAIN AND VAGUS NERVE IN
METABOLIC REGULATION AND A ROLE
FOR CHOLINERGIC SIGNALING
One of the first indications that the brain regulates body
metabolism came from studies performed by the 19th century
French physiologist Claude Bernard. He reported that electrically
stimulating the floor of the fourth ventricle in the brain
increased circulating blood glucose and induced a type of
transient diabetes, thus connecting the brain with glucose
and diabetes (Bernard, 1855). This intriguing brain-to-body
metabolism and diabetes link was not intensely studied as
the discovery of insulin in 1923 subsequently dominated the
diabetes field. However, recent studies have provided important
new insights into the role of the brain in the control of
peripheral metabolic function and in the context of obesity-
driven disorders, including type 2 diabetes. Accumulating
evidence indicates that the brain closely monitors peripheral
metabolic processes and plays a key role in regulating energy
intake and metabolic homeostasis (Morton et al., 2006).
The mechanisms involved in this regulation are complex,
involving cholecystokinin, leptin, and insulin signaling, and
several adiposity-related feedback loops (Morton et al., 2006;
van Dijk et al., 2011).
Extensive research has characterized the hypothalamus as
an important forebrain region in the regulation of metabolic
homeostasis (van Dijk et al., 2011). Neuronal circuitry in
the arcuate nucleus within the mediobasal hypothalamus
plays a major regulatory role in food intake and metabolism
mediating brain effects of leptin, insulin, melanocortins, and
other metabolic molecules (Morton et al., 2006; Andermann
and Lowell, 2017). For instance, the complex action of leptin
on feeding behavior importantly involves activation of an
appetite-suppressing population of pro-opiomelanocortin
neurons and inhibition of neurons that express agouti-
related protein and neuropeptide Y in the arcuate nucleus.
Through a circuitry involving other proximal hypothalamic
nuclei, such as the paraventricular nucleus and lateral
hypothalamic area, these neurons communicate with the
brainstem nucleus tractus solitarius (NTS) and promote afferent
vagus nerve-mediated satiety and meal termination (Morton
et al., 2006). Insulin also stimulates pro-opiomelanocortin
neurons, which in turn causes suppression of appetite-
promoting population of agouti-related protein neurons
(Guilherme et al., 2019). In addition, insulin action in the
arcuate nucleus is importantly implicated in the regulation of
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hepatic glucose production and adipose lipolysis (Konner et al.,
2007; Shin et al., 2017). Specific insulin signaling in agouti-
related peptide-expressing neurons mediates the suppression
of hepatic glucose production by this molecule (Konner
et al., 2007) while insulin action on pro-opiomelanocortin
neurons is linked to restraining adipose tissue lipolysis
(Shin et al., 2017).
The pro-opiomelanocortin neuronal circuit in the
hypothalamic arcuate nucleus was also identified as a major
mediator of the appetite-suppressing effect of nicotine, thus
providing a mechanistic insight into the apparent link between
smoking and suppressed appetite (Mineur et al., 2011).
α3β4nAChRs on these neurons have an essential role in
mediating the suppressive effects of nicotine and other more
selective agonists on food intake and weight gain in mice
(Andermann and Lowell, 2017). These and other studies
implicated brain α3β4 and other nAChRs, and the brain
cholinergic system in the regulation of feeding behavior (Jo
et al., 2002; Picciotto et al., 2012). As shown in Figure 1,
major components of this system are the basal forebrain
cholinergic system, comprised by several nuclei and the
mesopontine/brainstem cholinergic system represented by the
pedunculopontine and laterodorsal tegmental nuclei (Woolf
and Butcher, 2011; Ballinger et al., 2016; Hampel et al., 2018).
Basal forebrain cholinergic neurons innervate different cortex
areas, the hippocampus, amygdala, and other regions (Figure 1).
Among others, major projections of the cholinergic neurons in
the mesopontine nuclei include the thalamus and hypothalamus
(Figure 1). Cholinergic neurons residing in the brainstem dorsal
motor nucleus of the vagus (DMN) and nucleus ambiguus
(NA) provide peripheral axonal projections within the vagus
nerve (Figure 1). Recently, basal forebrain cholinergic signaling
was importantly implicated in the regulation of feeding
behavior using selective optogenetic modulation (Herman
et al., 2016; Figure 1). Both acute and chronic inactivation of
cholinergic neurons in the basal forebrain diagonal band of
Broca increases food intake while their stimulation results in
decreased food intake (Herman et al., 2016). It was proposed
that an extended brain network that regulates targets in the
hypothalamic arcuate nucleus may mediate these cholinergic
effects (Herman et al., 2016). In addition to nAChRs, muscarinic
acetylcholine receptors (mAChRs) importantly mediate brain
cholinergic neurotransmission and have also been associated
with peripheral metabolic regulation. For instance, cholinergic
mAChR-mediated activation in the hypothalamus results
in increased hepatic glycogen synthesis and this effect is
vagus nerve mediated (Shimazu et al., 1976; Matsushita
et al., 1979). In addition, cholinergic M1 mAChR-mediated
hypothalamic activation has also been shown to result in
increased pancreatic exocrine secretion through the vagus nerve
(Li et al., 2003; Figure 1).
The vagus nerve is a major conduit linking the brain and
periphery in the regulation of metabolism (Berthoud, 2008;
Andermann and Lowell, 2017; Metz and Pavlov, 2018). Sensory
(afferent) fibers within the vagus nerve with cell bodies in
the nodose ganglia communicate signals for alterations in
nutrients and metabolic molecules, including cholecystokinin,
FIGURE 1 | Brain cholinergic system: anatomy and functional control.
Important constituents of the brain cholinergic system are the basal forebrain
cholinergic system (BFCS) comprised of several nuclei, the mesopontine
pedunculopontine and laterodorsal tegmental nuclei (PPT and LDT), and
intraneurons in the striatum. Cholinergic neurons provide innervations to
different cortex areas, hippocampus, amygdala, olfactory bulb, hypothalamus
(HTh), thalamus, and other regions. In addition to its well-documented role in
the regulation of cognition, brain cholinergic signaling is implicated in the
regulation of appetite and feeding behavior, local brain inflammatory responses
(neuroinflammation), hepatic glycogen synthesis, pancreatic secretion, and
control of peripheral inflammation (through vagus nerve-mediated
mechanisms). Cholinergic neurons in the brainstem dorsal motor nucleus of
the vagus (DMN) and nucleus ambiguus (NA) provide axonal projections within
preganglionic efferent vagus nerve fibers. These long fibers interact with short
postganglionic neurons in proximity or within the innervated organs, including
the heart, lungs, gastrointestinal tract, liver, and pancreas. Acetylcholine (ACh)
released from these neurons interacts with muscarinic acetylcholine receptors
(mAChRs) on targeted cells and regulates several metabolic functions. ACh
also regulates (inhibits) the release of pro-inflammatory cytokines and
inflammation via alpha 7 nicotinic acetylcholine receptors (α7nAChRs) on
immune cells (see the text for more details). (A rodent brain is shown as a
substantial part of the information summarized is based on preclinical studies.)
leptin, and glucose from the gastrointestinal tract and the
hepatic portal system to the brainstem (Pavlov and Tracey, 2012;
Kaelberer et al., 2018; Figure 2). This communication involves
neural synaptic transmission that occurs on the timescale of
milliseconds, and slower humoral communication on the order
of minutes. These signals arrive at NTS in the brainstem
medulla oblongata, which is anatomically and functionally
linked to DMN. Efferent (motor) vagus nerve cholinergic
neurons originating from DMN and NA provide preganglionic
innervations to visceral organs and regulate a range of
vital cardiovascular, respiratory, and gastrointestinal functions,
mediated through mAChRs on the effector cardiac myocytes,
smooth muscle cells, and glandular cells (Figure 1). The
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efferent vagus nerve also regulates hepatic gluconeogenesis
and pancreatic exocrine and endocrine secretion (Schwartz,
1983; Pocai et al., 2005; Pavlov and Tracey, 2012). For
instance, efferent vagus nerve cholinergic signaling stimulates
insulin release in the pancreas through M3 mAChR-mediated
mechanism (Ruiz de Azua et al., 2011). In addition, mice
with selective pancreatic β cells deficiency of the M3 mAChR
have lower insulin secretion and impaired glucose tolerance
(Gautam et al., 2006). NTS, DMN, and the closely located
area postrema (a circumventricular organ) form the dorsal
vagal complex, with reciprocal neuronal connectivity with
hypothalamic nuclei and other forebrain regions, thus providing
an extended brain network in the control of metabolic
homeostasis (Pavlov and Tracey, 2012). The vagus nerve
through its afferent fibers is a major mediator of satiety and
a regulator of feeding behavior (Smith et al., 1981; Berthoud,
2008; Owyang and Heldsinger, 2011; Figure 2). Accordingly, a
recent study demonstrated the substantial efficacy of implanted
battery-free device-generated stimulation of afferent vagus nerve
fibers (associated with stomach peristalsis) in achieving and
maintaining weight loss in rats (Yao et al., 2018). This finding
suggests the possibility of specifically targeting abdominal
afferent vagus nerve fibers by bioelectronic devices as a
therapeutic approach in obesity.
VAGUS NERVE AND BRAIN
CHOLINERGIC SIGNALING IN
CONTROLLING INFLAMMATION
Inflammation is a vital physiological response to harmful stimuli,
including pathogen invasion and tissue injury through a number
of processes and pathways, including the activation of specific
immune cell types (e.g., neutrophils and macrophages) and
the release of inflammatory mediators (e.g., cytokines and
chemokines) (Chen and Nunez, 2010; Olofsson et al., 2017).
Inflammation is generally a localized event, which resolves and
then the body returns to homeostasis (Chen and Nunez, 2010;
Serhan and Levy, 2018). However, different forms of non-
resolved, exacerbated, or chronic inflammation cause secondary
tissue injury and mediate pathogenesis in sepsis, IBD, rheumatoid
arthritis, and many other diseases (Firestein, 2003; Tracey, 2007;
Chavan and Tracey, 2017). Therefore, controlling inflammation
is critically important in disease prevention and a useful
therapeutic strategy in disease treatment. In addition to immune
and hormonal regulation, research during the last 20 years
has demonstrated an important role of vagus nerve-mediated
neural mechanisms in controlling inflammation (Chavan and
Tracey, 2017). Several studies have shown that sensory vagus
neurons can be activated by cytokines, including IL-1β, TNF, and
other inflammatory molecules (Goehler et al., 2000; Steinberg
et al., 2016; Zanos et al., 2018). These peripheral inflammatory
alterations are communicated to the brainstem and in a reflex arc,
vagus nerve cholinergic anti-inflammatory output is generated
(Tracey, 2002).
These studies led to the concept of a physiological
immunoregulatory mechanism termed the inflammatory
reflex (Tracey, 2002). The efferent arm of this mechanism
was termed the cholinergic anti-inflammatory pathway
(Borovikova et al., 2000; Pavlov et al., 2003). Electrical VNS has
been instrumental in revealing the anti-inflammatory role of the
vagus nerve innervating the liver, gastrointestinal tract, pancreas,
and other organs in animal models (Borovikova et al., 2000; de
Jonge et al., 2005; Bonaz et al., 2018; Metz and Pavlov, 2018).
Cholinergic signaling is translated into suppression of pro-
inflammatory cytokine release via α7nAChR-mediated
signaling (Wang et al., 2003; Olofsson et al., 2012) and
intracellular mechanisms, including suppression of NF-κB
nuclear translocation, and JAK2/STAT3 activation (Figure 3)
(Guarini et al., 2004; de Jonge et al., 2005; Parrish et al., 2008).
In addition, recent studies have shown a mediating role for
inflammasome inhibition and cAMP signaling (Tarnawski
et al., 2018). Substantial advance in our understanding of the
inflammatory reflex was achieved by revealing the functional
cooperation between the vagus nerve and the splenic nerve
and identifying a subset of splenic T cells, containing the
enzyme choline acetyltransferase, as a source of acetylcholine
in this circuit (Rosas-Ballina et al., 2011; Figure 3). Identifying
the mediating role of the α7nAChR in the inflammatory
reflex generated a line of research demonstrating the anti-
inflammatory and disease-alleviating efficacy of α7nAChR
agonists in numerous murine models of inflammatory diseases
(Pavlov et al., 2007; Parrish et al., 2008; Pavlov and Tracey,
2015). Several studies have also shown that the inflammatory
reflex and its efferent arm – the cholinergic anti-inflammatory
pathway – can be activated through brain mAChR signaling. The
anti-inflammatory and beneficial metabolic effects of centrally
acting mAChR ligands and the AChE inhibitor galantamine
have been demonstrated in murine models of endotoxemia, IBD,
hemorrhagic shock, lupus, and other disorders and linked to the
inflammatory reflex (Pavlov et al., 2006, 2009; Lee et al., 2010; Ji
et al., 2014; Munyaka et al., 2014; Rosas-Ballina et al., 2015; Pham
et al., 2018). In addition to galantamine, the anti-inflammatory
effects of other AChE inhibitors and cholinergic drugs clinically
approved for the treatment of Alzheimer’s disease, such as
donepezil and rivastigmine, have also been demonstrated (Lataro
et al., 2015; Pavlov and Tracey, 2015; Zhang et al., 2016).
In addition to inflammation in the periphery, inflammation in
the CNS and specifically in the brain also occurs in response to
tissue damage and pathogens. Persistent neuroinflammation is a
characteristic feature of traumatic brain injury, sepsis, multiple
sclerosis, other neurodegenerative diseases, and other disorders
(Amor et al., 2014; Borst et al., 2018; Pavlov et al., 2018).
A link between inflammation, neuroinflammation, and cognitive
deterioration has also been identified (Nizri et al., 2008;
Terrando et al., 2011; Miller and Spencer, 2014; McManus
and Heneka, 2017; Borst et al., 2018). Of note, galantamine,
rivastigmine, and donepezil have been shown to alleviate
neuroinflammation and improve cognition in preclinical studies
(Nizri et al., 2008; Dasuri et al., 2016; Wang et al., 2018;
Figure 2). In addition, a very recent study demonstrated
that in addition to suppressing peripheral inflammation, VNS
also alleviates neuroinflammation and cognitive dysfunction in
murine endotoxemia (Huffman et al., 2019).
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FIGURE 2 | Cholinergic control of inflammation and metabolic derangements in obesity-driven disorders. Inflammation in obesity is a major driver of insulin
resistance and other metabolic derangements linked to an increased risk of cardiovascular disease, type 2 diabetes, NASH, and other disorders. Main factors that
contribute to this low-grade chronic inflammation are: adipokines and cytokines released from enlarged adipocytes and immune cells infiltrating the expanded white
adipose tissue; LPS as a result of microbiota alterations and increased intestinal permeability; and increased levels of free fatty acids. Inflammation and
neuroinflammation in obesity are also linked to cognitive impairment. The vagus nerve provides a major conduit for communication between the brain and the
periphery. Afferent (sensory) neurons residing in the nodose ganglia and terminating in the NTS detect alterations in peripheral inflammatory and metabolic molecules
and communicate this information to the brain. Signaling through efferent cholinergic fibers that originate in the dorsal motor nucleus (DMN) plays an important role in
controlling inflammation and metabolic derangements. Brain cholinergic signaling also is implicated in the regulation of cognition and controlling neuroinflammation.
Brain and peripheral (vagus nerve) cholinergic signaling can be explored for therapeutic benefit in obesity and obesity-driven conditions. Preclinical and clinical
studies have shown the efficacy of galantamine and other centrally acting acetylcholinesterase inhibitors, bioelectronic VNS, and α7nAChRs agonists in alleviating
inflammation, metabolic derangements, neuroinflammation, and in improving cognition (See text for details). (This figure was created with BioRender.)
CHOLINERGIC CONTROL OF
OBESITY-ASSOCIATED INFLAMMATION
AND METABOLIC DERANGEMENTS
Chronic low-grade inflammation is a characteristic pathological
feature of obesity and MetS (Eckel et al., 2005; Tilg and Moschen,
2006; Nathan, 2008; Gregor and Hotamisligil, 2011; Lumeng
and Saltiel, 2011; Pavlov and Tracey, 2012). Inflammation
in obesity is manifested by increased circulating levels of
classical pro-inflammatory cytokines, such as TNF and altered
levels of adipokines, including leptin, resistin, and adiponectin
(Tilg and Moschen, 2006; Lumeng and Saltiel, 2011; Pavlov
and Tracey, 2012). Expanded abdominal white adipose tissue
in obesity and the crosstalk between metabolically active
adipocytes and immune cells infiltrating the adipose tissue,
including macrophages, neutrophils, and T lymphocytes, have
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been identified as a major source of cytokines and adipokines
and contributors to this characteristic inflammation (Tilg and
Moschen, 2006; Nishimura et al., 2009; Pavlov and Tracey,
2012; Engin, 2017; Figure 2). Both enlarged adipocytes and
infiltrating immune cells release pro-inflammatory cytokines
such as TNF, interleukin-1 (IL-1β), and IL-6 (Pavlov and
Tracey, 2012; Engin, 2017). Increased circulating levels of
lipopolysaccharide (LPS, endotoxin) have been also detected in
obesity (Cani et al., 2007). Microbiota alterations in the gut
(increased LPS-containing microbiota) as a result of high-fat
diet intake and increased body weight, and the consequent
increased intestinal permeability have been associated with this
“metabolic endotoxemia,” which is another major contributor to
inflammation in obesity (Cani et al., 2007; Cani and Delzenne,
2009; Delzenne et al., 2011). LPS, acting through a toll-like
receptor 4 (TLR4)-mediated mechanism, triggers the release
of TNF and other pro-inflammatory cytokines, mediating pro-
inflammatory signals in liver, skeletal muscle, and adipose tissue
(Cani et al., 2007; Castanon et al., 2014). Another important
contributor to inflammation and other metabolic derangements
in obesity is the high levels of free fatty acids (Lumeng
and Saltiel, 2011). Acting through TLR4-mediated mechanisms
on adipocytes, macrophages, and hepatocytes, free fatty acids
trigger intracellular signaling resulting in NF-κB activation and
increased TNF and other pro-inflammatory cytokine release (Shi
et al., 2006; Baker et al., 2011; Lumeng and Saltiel, 2011; Pavlov
and Tracey, 2012). Inflammation in obesity is linked to insulin
resistance (Cani et al., 2007; Shoelson et al., 2007; Olefsky and
Glass, 2010; Vandanmagsar et al., 2011). For instance, TNF has
been shown to directly induce insulin resistance (Hotamisligil
et al., 1993; Hotamisligil et al., 1996). In addition, obesity-related
inflammation and insulin resistance are linked to fatty liver
disease and the development of non-alcoholic steatohepatitis
(NASH) (Shoelson et al., 2007; Carter-Kent et al., 2008; Lumeng
and Saltiel, 2011; Schuppan and Schattenberg, 2013; Figure 2).
Approaches based on electrical VNS have been successfully
explored in the treatment of obesity (Val-Laillet et al., 2010;
Malbert et al., 2017; Masi et al., 2018). Several studies have
also indicated the efficacy of targeting the inflammatory reflex
using pharmacological modalities in alleviating inflammation
and metabolic derangements interrelated in obesity-driven
conditions (Pavlov and Tracey, 2012; Figure 2). Administration
of nicotine (an α7nAChR agonist) to genetically obese db/db mice
lacking the leptin receptor and mice with high-fat diet-induced
obesity suppresses adipose tissue and systemic TNF levels (Wang
et al., 2011). Nicotine also decreases adipose tissue expression of
CCL2 and the macrophage marker F4/80, pointing to alleviation
of adipose tissue macrophage infiltration. In addition, α7nAChR
KO mice on a high-fat diet have increased M1 macrophage
infiltration and upregulated expression of TNF and CCL2 in
adipose tissue compared to WT controls (Wang et al., 2011).
Oral administration of the selective α7nAChR agonist TC-
7020 to db/db mice significantly lowers systemic TNF and this
effect is abrogated by co-administering methyllycaconitine – a
selective α7nAChR antagonist (Marrero et al., 2010). TC-7020
administration to db/db mice also reduces weight gain, food
intake and blood glucose, HbA1c, and triglyceride levels and
FIGURE 3 | Molecular mechanisms of cholinergic control of inflammation.
Efferent vagus nerve activity is translated into catecholamine-mediated
activation of T-cell-derived ACh release in the spleen and into direct ACh
release from efferent vagus nerve endings in other organs. Inhibition of NF-κB
nuclear translocation and activation of a JAK2-STAT3-mediated signaling
cascade in macrophages and other immune cells are implicated in cholinergic
α7nAChR-mediated control of pro-inflammatory cytokine production. ACh,
acetylcholine; β2AR, β2 adrenergic receptor; JAK2, Janus kinase 2; α7nAChR,
α 7 nicotinic acetylcholine receptor; NA, noradrenaline; NF-κB, nuclear factor
κB; STAT3, signal transducer and activator of transcription 3. (This figure was
originally published in Nature Reviews Endocrinology. 2012; 8: 743–754 and
is used here in agreement with Springer Nature copyright regulations for reuse
of author’s own work.)
these beneficial effects are also abrogated by methyllycaconitine
(Marrero et al., 2010). Importantly, administration of a JAK2
inhibitor significantly diminishes the TC-7020 effects on body
weight, food intake, and blood glucose levels, a finding that
suggests a link between α7nAChR- and JAK2-mediated signaling
(Marrero et al., 2010). An important role for vagus nerve
α7nAChR-mediated cholinergic signaling in experimental NASH
was also demonstrated (Nishio et al., 2017). In a murine model
of diet-induced NASH, α7nAChR KO chimeric mice (produced
by transplanting α7nAChR bone marrow cells into γ-irradiated
and Kupffer cell-depleted wild-type recipients) develop an
accelerated form of disease (Nishio et al., 2017). These mice have
significantly upregulated pro-inflammatory cytokine expression
and altered/abnormal lipid metabolic pattern. Selective hepatic
vagotomy in this model also results in increased TNF,
IL-12, and CCL2 (MCP-1) levels indicative for increased
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hepatic inflammation (Nishio et al., 2017). Using α7nAChR KO
mice, another recent study also demonstrated the tonic anti-
inflammatory and anti-fibrotic role of this receptor in models of
atherogenic high-fat diet- and methionine/choline-deficient diet-
induced NASH (Kimura et al., 2018). In these models, α7nAChR
deficiency resulted in exacerbated hepatic fibrosis, higher plasma
transaminase levels, and significantly increased Col1a1 gene-
encoding alpha-1 type I collagen (mediating liver fibrosis) Ccl2
and Tnf gene expression (Kimura et al., 2018).
As noted above, the inflammatory reflex can be activated
by the centrally acting cholinergic drug, the AChE
inhibitor galantamine (Pavlov et al., 2009; Ji et al., 2014;
Pham et al., 2018). Galantamine alleviates inflammation and
metabolic derangements in a high-fat diet-induced model
of obesity and MetS (Satapathy et al., 2011). Galantamine
treatment of mice with established obesity (after 8 weeks
on a high-fat diet) significantly lowers plasma IL-6, CCL2,
leptin, and resistin levels, and reduces body weight, food
intake, and abdominal white adipose depots (Satapathy et al.,
2011). Galantamine also decreases blood glucose, plasma
insulin, and cholesterol levels, and alleviates insulin resistance
and fatty liver disease in these mice (Satapathy et al., 2011).
Recent work has also shown that galantamine has anti-diabetic
effects in murine models (Ali et al., 2015; Hanes et al., 2015).
Of note, the anti-diabetic effects of galantamine treatment
of rats with established n5-STZ diabetes are greater than
the effects of the anti-diabetic drug vildagliptin also used
in the study (Ali et al., 2015). These and other preclinical
studies indicate that neural cholinergic modulation, either
pharmacologically or through bioelectronic VNS, can be
further explored to treat obesity-related inflammatory and
metabolic derangements.
NEUROINFLAMMATION AND
COGNITIVE IMPAIRMENT IN
OBESITY-DRIVEN DISORDERS: A
CHOLINERGIC LINK TO TREATMENT
In addition to inflammation in the periphery, obesity is
associated with neuroinflammation (Miller and Spencer, 2014;
Guillemot-Legris and Muccioli, 2017; Lainez et al., 2018;
Figure 2). This neuroinflammation occurs in multiple brain
structures, including the hypothalamus, hippocampus, amygdala,
neocortex, and cerebellum, and there is evidence that it is
sex-specific (Miller and Spencer, 2014; Guillemot-Legris and
Muccioli, 2017; Lainez et al., 2018). In these brain regions,
diet-induced obesity is associated with increased levels of
pro-inflammatory cytokines along with higher expression of
NF-κB and TLR4, two important molecular mediators of
innate immune responses (Biessels et al., 2014). This type
of neuroinflammation may involve recruitment of peripheral
immune cells (Miller and Spencer, 2014; Lainez et al.,
2018) and there is evidence that peripheral inflammation
precipitates brain inflammation (Miller and Spencer, 2014;
Guillemot-Legris and Muccioli, 2017). Studies have linked
obesity with cognitive impairment and both inflammation
and neuroinflammation may play a mediating role in this
context (Pistell et al., 2010; Sellbom and Gunstad, 2012; Miller
and Spencer, 2014). Association between obesity and diabetes
derangements, and increased risk of developing dementia has
also been indicated (Whitmer et al., 2005; Strachan et al., 2011;
Biessels et al., 2014).
The brain cholinergic system (Figure 1) plays a major
role in the regulation of memory, attention, and learning
(Ballinger et al., 2016; Hampel et al., 2018). Cholinergic
neurodegeneration predominantly affecting the basal forebrain
neurons and neuroinflammation are hallmarks of brain
pathology in Alzheimer’s disease (Heneka et al., 2015; Hampel
et al., 2018). As mentioned earlier, centrally acting AChE
inhibitors, including galantamine, donepezil, and rivastigmine,
are clinically approved cholinergic drugs for treating cognitive
impairment in Alzheimer’s disease (Hampel et al., 2018). There
is accumulating experimental evidence that brain cholinergic
dysfunction is implicated in cognitive impairment in obesity
as recently reviewed (Martinelli et al., 2017). High-fat diet-
induced obesity in mice results in increased brain AChE
expression and neuroinflammation manifested by microglial
activation (Dasuri et al., 2016). Of note, donepezil treatment
suppresses brain microglial activation and neuroinflammation
in this model (Dasuri et al., 2016). There is also experimental
evidence that enhancing cholinergic signaling by galantamine
and rivastigmine also results in anti-inflammatory effects in
the brain and improved cognition (Nizri et al., 2008; Wang
et al., 2018). It is interesting and important that many brain
regions affected by neuroinflammation in obesity, including
the hypothalamus, hippocampus, amygdala, and cortex receive
cholinergic innervations (Figure 1). Whether cholinergic
dysfunction facilitates neuroinflammation in obesity is a
question that remains to be further addressed.
Together these findings paint a picture of peripheral
inflammation and neuroinflammation interrelated with cognitive
impairment and cholinergic dysfunction in obesity. An improved
understanding of the relationship between these elements of
pathology in obesity would provide a solid rationale for designing
new therapeutic approaches.
CLINICAL TRANSLATION OF
CHOLINERGIC MODULATION IN
OBESITY-DRIVEN DISORDERS
Obesity and obesity-related conditions, including MetS, type 2
diabetes, NASH, and cardiovascular disease, present a substantial
health burden. Current treatment options are limited to lifestyle
modifications, non-specific drugs, or insulin injections for those
with type 2 diabetes. Unfortunately, lifestyle changes and dietary
modifications are only temporarily effective for durable weight
loss. For instance, a study with obese women subjected to
caloric restrictions and behavioral therapy showed that nearly
50% of lost weight is regained within 1 year and almost all
of it is regained within 5 years (Wadden et al., 1989). Non-
specific weight loss medications have a blemished track record
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and are also often ineffective as long-term solutions. Obesity-
related type 2 diabetes is a progressive disorder and most
patients eventually require treatment with insulin to control
blood glucose levels as β cells in the pancreas lose their ability to
produce insulin (Kahn and Hull, 2006). While generally effective,
injectable insulin can produce side effects such as hypoglycemia,
hunger, weakness, irritability, and requires frequent monitoring
of blood glucose levels. The current studies on closed-loop
control systems in diabetes known as “the artificial pancreas” may
provide a significant advance in overcoming these disadvantages
(Kovatchev, 2018). Other treatment options for obesity-driven
disorders include surgical interventions with bariatric surgery
which can result in long-term weight loss, but surgical treatments
come with significant risks and are only recommended for the
morbidly obese (Chang et al., 2014). Thus, the limitations of
currently available treatments for obesity-driven disorders invite
an exploration of new targets and pathways. In this context,
targeting inflammation remains an attractive area for further
exploration (Goldfine et al., 2011; Esser et al., 2015).
Based on preclinical evidence for beneficial anti-inflammatory
and metabolic efficacy, cholinergic modulation in treating
obesity-driven disorders is of specific interest (Figure 2).
An additional advantage is that cholinergic drugs such as
centrally acting AChE inhibitors and bioelectronics, including
implanted devices for VNS are already clinically approved
for other indications. Galantamine is a centrally acting
AChE inhibitor that has been FDA approved to treat the
cognitive impairment in patients with Alzheimer’s disease
in the United States for more than a decade (Hampel et al.,
2018). There is a large amount of safety information available,
making galantamine an attractive candidate to be clinically
repurposed. A major obesity-driven disorder is MetS, a
cluster of conditions that includes high blood pressure, high
blood glucose levels, abdominal obesity, and dyslipidemia
(Eckel et al., 2005; Grundy, 2008). The combination of these
conditions within MetS generates a significantly higher
risk of developing type 2 diabetes, cardiovascular disease,
cancer, and other life-threatening and debilitating diseases,
compared to the individual condition-related risk (Eckel
et al., 2005). Apart from lifestyle modifications, treating
MetS as a whole presents a significant challenge, and usually
several medications targeting the separate risk factors are
prescribed. Inflammation as a driver of insulin resistance
and other pathogenesis in MetS provides an attractive
therapeutic target (Esser et al., 2015). Based on preclinical
findings, the efficacy of galantamine in alleviating inflammation
and insulin resistance alongside other metabolic indices in
people with MetS was recently studied in a randomized,
placebo-controlled, double blind trial (Consolim-Colombo
et al., 2017). Relatively short treatment (for 12 weeks) with
galantamine in doses clinically approved for Alzheimer’s disease,
significantly decreased plasma TNF and leptin levels and
increased IL-10 and adiponectin levels (Consolim-Colombo
et al., 2017). Galantamine treatment vs. placebo also modulated
the autonomic neural regulation, as determined by heart
rate variability analysis, toward parasympathetic (vagal)
predominance (Consolim-Colombo et al., 2017).
Another approach of cholinergic neuromodulation to explore
in treating obesity-driven diseases is VNS. The feasibility of
this approach for treating immune and metabolic derangements
in humans was recently demonstrated in clinical trials with
patients with IBD and rheumatoid arthritis (Bonaz et al.,
2016; Koopman et al., 2016). Interestingly, humans with
obesity have reduced vagal tone (Karason et al., 1999;
Carnethon et al., 2003), coexisting with inflammation and
metabolic deterioration. Since activation of vagal efferents
attenuates immune and metabolic dysfunction, it is possible
that reduced vagal cholinergic output plays a causative role
in immune and metabolic dysregulation. VNS is clinically
approved for epilepsy and depression (Ben-Menachem, 2001;
Bonaz, 2018). Of note, patients receiving VNS for medication-
refractory epilepsy or depression have also reported weight
loss, in as high as 60% of the patients tested (Burneo
et al., 2002; Pardo et al., 2007). While these patients were
receiving VNS for other non-metabolic indications, these
weight loss effects suggest the possible therapeutic utility
of VNS in obesity-associated conditions. VNS implants for
epilepsy and depression have been routinely used and the
therapy is well-tolerated (Ben-Menachem, 2001). The risks
associated with VNS implantation surgery are low and side
effects of the stimulation itself are minor, typically limited
to cough and hoarseness (Sackeim et al., 2001; O’Reardon
et al., 2006). A recent study demonstrated that specific
vagus nerve signals in response to alterations in cytokine
levels can be recorded (Zanos et al., 2018). Therefore,
in the future, an advanced version of bioelectronic vagus
nerve modulation could potentially provide the additional
advantage of enabling “closed-loop” control of immune and
metabolic dysfunctions. Preclinical research has also indicated
the possibility to use α7nAChR agonists in treating inflammatory
and metabolic derangements in human obesity. This is
also supported by demonstrating α7nAChR expression in
human adipocytes and its role in controlling pro-inflammatory
gene expression (Cancello et al., 2012). Furthermore, obesity
is associated with significant decrease in human adipocyte
α7nAChR and weight loss partially restores its expression
(Cancello et al., 2012).
Cognitive deterioration and an increased risk of developing
dementia are documented in obesity, MetS, and type 2 diabetes
(Strachan et al., 2011; Biessels et al., 2014). This cognitive
dysfunction is interrelated with inflammatory and metabolic
derangements and treating these conditions is challenging
(Strachan et al., 2011; Guillemot-Legris and Muccioli, 2017).
An important point is that while designing new approaches for
treating obesity and related conditions, one should account for
their effects on the brain in relation to cognitive impairment
(Strachan et al., 2011). The cholinergic system in the brain
has a key role in the regulation of cognition (Picciotto et al.,
2012; Ballinger et al., 2016). Numerous studies have evaluated
galantamine, donepezil, and rivastigmine as cognitive enhancers
and these drugs are in current clinical use for the symptomatic
treatment of Alzheimer’s disease. As recently demonstrated,
galantamine has beneficial anti-inflammatory and metabolic
effects in patients with MetS (Consolim-Colombo et al., 2017).
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Therefore, future developments with galantamine and other
centrally acting AChE inhibitors in the treatment of patients
with obesity-associated disorders may include assessing the
potential benefit of these drugs on cognition. VNS has
been also associated with pro-cognitive effects especially in
the domains of verbal recognition, memory, and executive
function (Groves and Brown, 2005; Vonck et al., 2014).
The precise mechanisms of these VNS pro-cognitive effects
are largely unknown and one possibility that remains to be
explored is a mediating role of brain cholinergic signaling.
Recent findings have indicated that NTS afferent vagus nerve
signaling reaches basal forebrain cholinergic nuclei innervating
the hippocampus and cortex and implicated in cognitive
regulation (Suarez et al., 2018). These studies and other
clinical trials currently underway (ClinicalTrials.gov Identifier:
NCT02365285) generate a growing platform for further studies
on the therapeutic utility of cholinergic modulation in obesity-
associated disorders.
CONCLUDING REMARKS
In obesity and obesity-associated conditions, immune and
metabolic dysregulation result in chronic systemic inflammation,
neuroinflammation, exacerbated insulin resistance, fatty
liver disease, cognitive impairment, and other pathological
manifestations. An improved understanding of this complex
pathology requires providing new insight into the regulatory
role of the nervous system. Neural circuitry, including vagus
nerve cholinergic signaling, plays a major role in controlling
metabolic and immune homeostasis (Figures 1–3). Vagus
nerve cholinergic signaling within the inflammatory reflex
has an important regulatory role in the crosstalk between
immune and metabolic alterations in obesity-driven disorders.
Activation of cholinergic signaling by VNS, α7nAChR agonists,
and centrally acting drugs such as galantamine results in
anti-inflammatory effects, alleviation of insulin resistance and
hepatic steatosis, and other beneficial effects in murine models
of obesity, MetS, NASH, and type 2 diabetes. This large
body of preclinical evidence and the fact that both centrally
acting AChE inhibitors and VNS are already in clinical use
provide a rationale for expanding these approaches into clinical
settings of obesity. A recent clinical trial with galantamine
in MetS demonstrated the translational applicability of this
research and the anti-inflammatory and beneficial metabolic
effects of AChE inhibitors (Consolim-Colombo et al., 2017).
Enhancing brain cholinergic signaling by these drugs and the
use of VNS to alleviate obesity-associated brain pathology,
including neuroinflammation and cognitive deterioration in
humans, are feasible approaches that remain to be studied.
Recent discoveries of gut–brain neural circuits that involve
the vagus nerve (Han et al., 2018; Kaelberer et al., 2018) and
future preclinical research using advances in molecular genetics
within the growing field of bioelectronic medicine (Olofsson
and Tracey, 2017; Pavlov and Tracey, 2019) will improve our
understanding of neural regulation of immunity and metabolism
and its implications in obesity. This research holds the potential
to identify new therapeutic avenues for alleviation of the
obesity disease burden.
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